93 related articles for article (PubMed ID: 10854565)
1. Treatment of large cell lymphoma with the Fi2 regimen (doxorubicin, vincristine, cyclophosphamide, bleomycin and prednisone): 25-year experience.
Bellesi G; Rigacci L; Longo G; Alterini R; Bernardi F; Messori A; Trippoli S; Vaiani M; Carrai V; Rossi Ferrini P
Oncol Rep; 2000; 7(4):891-6. PubMed ID: 10854565
[TBL] [Abstract][Full Text] [Related]
2. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
3. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
Derenzini E; Stefoni V; Pellegrini C; Fina MP; Broccoli A; Venturini F; Gandolfi L; Pileri SA; Martelli M; Petti MC; Perrotti A; De Renzo A; Zaja F; Baccarani M; Zinzani PL
Leuk Lymphoma; 2009 Nov; 50(11):1824-9. PubMed ID: 19814687
[TBL] [Abstract][Full Text] [Related]
5. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H;
Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442
[TBL] [Abstract][Full Text] [Related]
6. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
7. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
8. Late relapse in patients with diffuse large-cell lymphoma treated with MACOP-B.
Lee AY; Connors JM; Klimo P; O'Reilly SE; Gascoyne RD
J Clin Oncol; 1997 May; 15(5):1745-53. PubMed ID: 9164181
[TBL] [Abstract][Full Text] [Related]
9. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
10. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
11. Interferon alfa 2b as maintenance therapy in poor risk diffuse large B-cell lymphoma in complete remission after intensive CHOP-BLEO regimens.
Avilés A; Cleto S; Huerta-Guzmán J; Neri N
Eur J Haematol; 2001 Feb; 66(2):94-9. PubMed ID: 11168516
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
Murohashi I; Kashimura T; Tominaga K; Wakao D; Takahashi T; Akiba M; Kishimoto K; Yoshida K; Yagasaki F; Itoh Y; Sakata T; Kawai N; Itoh K; Suzuki T; Matsuda A; Hirashima K; Bessho M
Leuk Res; 2002 Mar; 26(3):229-34. PubMed ID: 11792410
[TBL] [Abstract][Full Text] [Related]
13. Similar outcome of treatment of B-cell and T-cell diffuse large-cell lymphomas: the Stanford experience.
Kwak LW; Wilson M; Weiss LM; Doggett R; Dorfman RF; Warnke RA; Horning SJ
J Clin Oncol; 1991 Aug; 9(8):1426-31. PubMed ID: 1712837
[TBL] [Abstract][Full Text] [Related]
14. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
15. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
16. Low-dose ACOP-B and VABE: weekly chemotherapy for elderly patients with advanced-stage diffuse large-cell lymphoma.
O'Reilly SE; Klimo P; Connors JM
J Clin Oncol; 1991 May; 9(5):741-7. PubMed ID: 1707954
[TBL] [Abstract][Full Text] [Related]
17. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
18. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study.
Vitolo U; Bertini M; Brusamolino E; Cavallero GB; Comotti B; Gallo E; Ghio R; Levis A; Luxi G; Meneghini V
J Clin Oncol; 1992 Feb; 10(2):219-27. PubMed ID: 1370690
[TBL] [Abstract][Full Text] [Related]
19. Advances in chemotherapy for large cell lymphoma.
Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW
Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781
[TBL] [Abstract][Full Text] [Related]
20. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).
Armitage JO; Dick FR; Corder MP; Garneau SC; Platz CE; Slymen DJ
Cancer; 1982 Nov; 50(9):1695-702. PubMed ID: 6749279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
